■ Théa Pharma Inc has completed the acquisition of 7 branded ophthalmic products from Akorn Operating Company LLC.

“As we expand our US presence, we are excited to embrace this popular portfolio of ophthalmic products that are widely recognized for the difference they make in patients’ lives,” said Susan Benton, Théa’s general manager, and head of the US business. “The acquisition of these products further demonstrates Théa’s commitment and mission to serve the doctors that treat anterior segment and ocular surface conditions. Our skilled and knowledgeable sales force is well positioned to increase awareness, drive growth, and expand accessibility for these widely utilized offerings.”

Théa acquired 7 products under the deal, including established glaucoma therapies Zioptan, Cosopt, Cosopt PF, and Betimol, as well as Azasite, Akten, and the ocular surface repair agent AcellFX.